See more : Nintendo Co., Ltd. (7974.T) Income Statement Analysis – Financial Results
Complete financial analysis of Forte Biosciences, Inc. (FBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Forte Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Regeneron Pharmaceuticals, Inc. (REGN) Income Statement Analysis – Financial Results
- Napco Security Technologies, Inc. (NSSC) Income Statement Analysis – Financial Results
- Shandong Longquan Pipeline Engineering Co.,LTD (002671.SZ) Income Statement Analysis – Financial Results
- Aroundtown SA (AANNF) Income Statement Analysis – Financial Results
- Bénéteau S.A. (BEN.PA) Income Statement Analysis – Financial Results
Forte Biosciences, Inc. (FBRX)
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.04M | 41.00K | 49.00K | 51.00K |
| Cost of Revenue | 9.00K | 0.00 | 36.00K | 54.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | -36.00K | -54.00K | -11.00K | 18.04M | 41.00K | 49.00K | 51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.86M | 5.59M | 13.85M | 10.00M | 2.68M | 50.46M | 29.11M | 27.22M | 19.17M |
| General & Administrative | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 265.68K | 8.56M | 4.52M | 3.83M |
| Selling & Marketing | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 12.54M | -292.00K | -255.00K | -232.00K |
| SG&A | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 12.81M | 8.27M | 4.27M | 3.60M |
| Other Expenses | -1.00 | 17.00K | -222.00K | -205.00K | -6.85K | 0.00 | 0.00 | -50.00K | 0.00 |
| Operating Expenses | 32.48M | 13.90M | 21.49M | 14.23M | 4.06M | 63.26M | 37.38M | 31.49M | 22.77M |
| Cost & Expenses | 32.49M | 13.90M | 21.49M | 14.23M | 4.06M | 63.89M | 37.67M | 31.74M | 23.01M |
| Interest Income | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 595.00K | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 173.38K | 1.93M | -1.84M | -102.00K | |
| Depreciation & Amortization | 9.00K | 36.00K | 36.00K | 54.00K | 11.00K | 625.00K | 292.00K | 255.00K | 232.00K |
| EBITDA | -32.48M | -13.90M | -21.45M | -46.43M | -4.05M | -43.69M | -36.71M | -31.17M | -22.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -250.77% | -91,065.85% | -64,155.10% | -44,552.94% |
| Operating Income | -32.49M | -13.90M | -21.49M | 17.83M | -4.06M | -45.85M | -37.63M | -31.69M | -22.95M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -254.23% | -91,778.05% | -64,675.51% | -45,007.84% |
| Total Other Income/Expenses | 1.01M | 17.00K | -222.00K | -205.00K | -5.00K | -1.40M | -1.30M | -1.79M | -102.00K |
| Income Before Tax | -31.48M | -13.88M | -21.71M | -46.49M | -4.07M | -47.26M | -38.93M | -33.48M | -23.06M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -262.01% | -94,948.78% | -68,322.45% | -45,207.84% |
| Income Tax Expense | 0.00 | -17.00K | -200.56K | 32.06M | -2.52K | 1.70M | -2.60M | -3.67M | -204.00K |
| Net Income | -31.48M | -13.86M | -21.71M | -78.54M | -4.07M | -48.96M | -38.93M | -33.48M | -23.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -271.43% | -94,948.78% | -68,322.45% | -45,207.84% |
| EPS | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| EPS Diluted | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| Weighted Avg Shares Out | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
| Weighted Avg Shares Out (Dil) | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
FBRX Stock: 82.3% Decrease Explanation
The stock price of Forte Biosciences, Inc. (NASDAQ: FBRX) fell by 82.3% yesterday. This is why it happened.
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Forte Biosciences, Inc. (“Forte” or “the Company”) (NASDAQ: FBRX) for violations of the securities laws. The investigation...
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.
Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate
Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.
Why Forte Biosciences Stock Is Down Over 80% Today
Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are appreciative of the clinical trial sites and the patients for participating in...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).
Why Forte Biosciences Stock Is Imploding Today
The company announced dismal results from a phase 2 study of its only pipeline candidate.
Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment
Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its lead product candidate FB-401, a treatment for atopic dermatitis....
Forte Biosciences Just Plummeted 80%: Here's Why
A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug FB-401 failed to meet a statistical significance, the company said.
Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint...
Source: https://incomestatements.info
Category: Stock Reports